Discover the groundbreaking strategy that could redefine pharmaceutical launches and propel your product’s success across North America. In the realm of pharmaceutical launches, a paradigm shift is underway, challenging the conventional sequential approach and calling for…
Achieving equity within healthcare is a harrowing but imperative goal for the industry. Lack of safe housing and healthy food, low income, ethnicity, race, rural living and other social determinants of health (SDOH) can have a…
Pharmaceutical manufacturers specializing in Rare Disease, Oncology, Personalized Cancer Immunotherapy, and Cell and Gene therapies encounter a range of complex challenges, including advancements in medicine and technology, changing patient and provider needs, market access, regulatory pathways,…
“Elevating Field Reimbursement Managers’ Performance through Customer-based Insights and Comparative Data,” authored by David Frey, Principal, Specialty Consulting, EVERSANA and Lee Ann Steadman, Senior Vice President, Specialty Consulting, EVERSANA explores the evolving role of Field Reimbursement…
EVERSANA is raising the questions the industry is thinking but is too afraid to ask aloud: Has omnichannel lived up to its promise of the “right message at the right time” to drive meaningful results that…
Providing services to patients in a digital world requires a delicate balance of blending high-tech and high-touch solutions. A majority of patients want the option to guide their own treatment journeys with ease and on their…
Acquiring all the necessary information to initiate patients’ treatment can sometimes feel like a bad game of Telephone to HCPs and their staff. Missing or inaccurate details that can require multiple phone calls, emails or faxes to…
Launching new therapies is a vast undertaking for any pharmaceutical company. Setting up a product for success requires a great deal of expense, research, strategic planning and effective collaboration, just to name a few essential elements. EVERSANA’s National…
A combination of industry challenges and an influx of complex therapies in the market, have impacted Medical Science Liaisons (MSLs), Clinical Trial Liaisons (CTLs) and Clinical Nurse Educators (CNEs). Susan Giacalone, MSN, BCMAS, MSL-BC, Vice President,…
Life sciences companies need to shift from the mindset of a pharmaceutical manufacturer of the twentieth, to that of the digital healthcare company of the twenty-first. Reps remain important, but they need to be empowered to succeed.…